药品名称 | ASACOL | 申请号 | 019651 | 产品号 | 001 | 活性成分 | MESALAMINE | 市场状态 | 停止上市 | 剂型或给药途径 | TABLET, DELAYED RELEASE;ORAL | 规格 | 400MG | 治疗等效代码 | | 参比药物 | 否 | 批准日期 | 1992/01/31 | 申请机构 | ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
| 化学类型 | New dosage form | 审评分类 | Priority review drug |
|
|
|
与本品相关的市场独占权保护信息 | 独占权代码 | 失效日期 | 无 | 历史市场独占权保护信息 | 无 |
|
与药品注册相关的信息 | 申请号 | 修订号 | 审批结论 | 公开文档类型 | 文档创建时间 | 获取文档 | 019651 | 025 | AP | Letter | 2015/05/28 | 下载 | 019651 | 025 | AP | Label | 2015/05/29 | 下载 | 019651 | 024 | AP | Letter | 2013/10/21 | 下载 | 019651 | 024 | AP | Label | 2013/10/22 | 下载 | 019651 | 023 | AP | Letter | 2010/05/28 | 下载 | 019651 | 023 | AP | Label | 2010/05/28 | 下载 | 019651 | 020 | AP | Label | 2009/10/06 | 下载 | 019651 | 020 | AP | Letter | 2009/11/12 | 下载 | 019651 | 016 | AP | Letter | 2007/04/20 | 下载 | 019651 | 005 | AP | Review | 2003/06/18 | 下载 |
|
药品注册审批历史信息 | 申请号 | 修订号 | 审批结论 | 审批日期 | 审批内容 | 019651 | 026 | AP | 2015/09/16 | Manufacturing Change or Addition | 019651 | 025 | AP | 2015/05/27 | Efficacy Supplement with Clinical Data to Support | 019651 | 024 | AP | 2013/10/18 | Supplement | 019651 | 023 | AP | 2010/05/24 | Labeling Revision | 019651 | 020 | AP | 2009/09/14 | Labeling Revision | 019651 | 016 | AP | 2007/04/10 | Labeling Revision | 019651 | 013 | AP | 2000/09/05 | Control Supplement | 019651 | 012 | AP | 2000/04/25 | Control Supplement | 019651 | 011 | AP | 2000/08/14 | Labeling Revision | 019651 | 010 | AP | 2000/08/14 | Labeling Revision | 019651 | 009 | AP | 1997/07/08 | Manufacturing Change or Addition | 019651 | 008 | AP | 1997/01/31 | Control Supplement | 019651 | 007 | AP | 1996/11/25 | Control Supplement | 019651 | 006 | AP | 1996/08/30 | Labeling Revision | 019651 | 005 | AP | 1997/08/19 | New or Modified Indication | 019651 | 004 | AP | 1996/05/06 | Control Supplement | 019651 | 003 | AP | 1996/05/06 | Manufacturing Change or Addition | 019651 | 002 | AP | 1995/11/26 | Control Supplement | 019651 | 001 | AP | 1993/05/27 | Labeling Revision | 019651 | 000 | AP | 1992/01/31 | Approval |
|